Ocular Therapeutix OCUL Institutional Ownership

Updated Oct 11, 2026

Ocular Therapeutix, Inc (NASDAQ:OCUL) appeared in the 13F filings of 261 institutional investors for the quarter ended June 30, 2026.

• These investors held 90.93% of Ocular Therapeutix's outstanding shares at the end of Q2 2026, down from 92.38% in Q1 2026.
• Total shares held in OCUL fell 1.20% from Q1 2026; the number of holders rose 43.41% from Q2 2025.
• Of these 261 holders, 138 added to their positions, 80 reduced their stakes and 43 left their positions unchanged.
• Combined, institutional investors held 204.55Mn shares of OCUL as of Q2 2026, down 2.48Mn from the prior quarter and up 55.06Mn from a year earlier.
• As of June 30, 2026, FMR LLC held the largest stake in Ocular Therapeutix with 32.84Mn shares, or 14.60% of shares outstanding.
• The largest position increases in OCUL for Q2 2026 were by BlackRock, Inc. (+3.24Mn shares), Dimensional Fund Advisors LP (+2.13Mn shares), T. Rowe Price Associates Inc (+1.73Mn shares), Logos Global Management LP (+1.45Mn shares) and Nuveen, LLC (+1.29Mn shares).
• The largest position reductions in OCUL for Q2 2026 were by AllianceBernstein L.P. (-3.9Mn shares), Point72 Asset Management, L.P. (-2.24Mn shares), Octagon Capital Advisors LP (-1.09Mn shares), Renaissance Technologies LLC (-769.23K shares) and Marshall Wace, LLP (-614.77K shares).
• According to Business Quant data, the leading holders of OCUL for Q2 2026 were FMR LLC (32.84Mn shares), Deep Track Capital, LP (19.69Mn shares), BlackRock, Inc. (19.38Mn shares), Avoro Capital Advisors LLC (12.54Mn shares), Summer Road LLC (12.21Mn shares), Venrock Adviser, LLC (10.35Mn shares), Vanguard Capital Management LLC (8.83Mn shares), T. Rowe Price Associates Inc (7.62Mn shares), Logos Global Management LP (5.3Mn shares) and State Street Corp (5.23Mn shares).